1.Research progress in hirudin fusion protein--review.
Chuan-Ling ZHANG ; Ai-Ping YU ; Ji-De JIN ; Chu-Tse WU
Journal of Experimental Hematology 2007;15(1):215-218
Natural hirudin extracted from the secretion of medical leech salivary gland is a single-chain peptide containing 65 aminoacid residues with molecular weight of 7000 D, and exists in three isomers of HV1, HV2 and HV3. Hirudin possesses three disulfide bridges forming the structure of core cyclic peptides, which binds to the catalytic site of thrombin so as to inhibit the catalysis of thrombin. Its c-terminus rich in acidic aminoacid residues possesses hydrophilicity, and is free on the molecular surface, and can bind with fibrin recognition site of hirudin. The minimal segment of 12 - 16 C-terminal acidic residues keeps the minimal activity of anti-thrombosis. Thus, hirudin, as a potent and specific inhibitor of thrombin, can be used to protect from and to treat clinically thrombosis. As it has some disadvantages such as short half-life, bleeding side-effect and mono-function, and so on, hirudin has been fused with some other functional proteins in recent years. The obtained fusion proteins can prolong the half life of hirudin, or relieve it bleeding side effect, or bring new functions, such as thrombolysis, inhibiting the platelet aggregation, targeting specifically. The research progress in hirudin fusion protein was summarized in this review.
Anticoagulants
;
pharmacology
;
Delayed-Action Preparations
;
Drug Delivery Systems
;
Glucokinase
;
biosynthesis
;
genetics
;
pharmacology
;
Hirudins
;
biosynthesis
;
genetics
;
pharmacology
;
Humans
;
Platelet Aggregation Inhibitors
;
pharmacology
;
Recombinant Fusion Proteins
;
biosynthesis
;
genetics
;
pharmacology
;
Urokinase-Type Plasminogen Activator
;
biosynthesis
;
genetics
;
pharmacology
2.HNF1 and/or HNF3 may contribute to the tissue specific expression of glucokinase gene.
Ji Young CHA ; Ha Il KIM ; Seung Soon IM ; Tian Zhu LI ; Yong Ho AHN
Experimental & Molecular Medicine 2001;33(2):59-63
A possible role of hepatocyte nuclear factor 1 (HNF1) or HNF3, a predominant trans-acting factors of hepatic or pancreatic beta-cells, was examined on the tissue specific interdependent expression of glucokinase (GK) in liver, H4IIE, HepG2, HIT-T15 and MIN6 cell line. The tissues or cell lines known to express GK showed abundant levels of HNF1 and HNF3 mRNA as observed in liver, H4IIE, HepG2, HIT-T15 and MIN6 cells, whereas they were not detected in brain, heart, NIH 3T3, HeLa cells. The promoter of glucokinase contains several HNF3 consensus sequences and are well conserved in human, mouse and rat. Transfection of the glucokinase promotor linked with luciferase reporter to liver or pancreatic beta cell lines showed high interacting activities with HNF1 and HNF3, whereas minimal activities were detected in the cells expressing very low levels of HNFs. The binding of HNF1 or HNF3 to the GK promoter genes was confirmed by electrophoretic mobility shift assay (EMSA). From these data, we propose that the expression of HNF1 and/or HNF3 may, in part, contribute to the tissue specific expression of GK.
3T3 Cells
;
Animal
;
Blotting, Northern
;
Cell Line
;
Cell Nucleus/metabolism
;
Cells, Cultured
;
DNA-Binding Proteins/genetics/*physiology
;
Genes, Reporter
;
Glucokinase/*biosynthesis/*genetics
;
Hela Cells
;
Human
;
Liver/metabolism
;
Luciferase/metabolism
;
Mice
;
Models, Genetic
;
Nuclear Proteins/genetics/*physiology
;
Plasmids/metabolism
;
Promoter Regions (Genetics)
;
Protein Binding
;
Rats
;
Support, Non-U.S. Gov't
;
Tissue Distribution
;
Transcription Factors/genetics/*physiology
;
Transcription, Genetic
;
Transfection